| Name | (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide |
|---|---|
| Synonyms |
Cyclopropanecarboxamide, 2-[[(2,4-dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)-, (1R,2S)-
(1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (1R,2S)-2-{[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide lemborexant |
| Description | Lemborexant (E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development for treatment of insomnia. |
|---|---|
| Related Catalog |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 596.1±50.0 °C at 760 mmHg |
| Molecular Formula | C22H20F2N4O2 |
| Molecular Weight | 410.417 |
| Flash Point | 314.3±30.1 °C |
| Exact Mass | 410.155426 |
| PSA | 77.00000 |
| LogP | 3.16 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.619 |
| Storage condition | 2-8℃ |